uploads/2018/03/family-515530_1280.jpg

What Analysts Recommend for Amedisys and Peers in March 2018

By

Updated

Company overview

Amedisys (AMED) is a healthcare services company with a focus on providing home care through three segments: home health, hospice, and personal care. The company is one of the largest pure-play providers of home health and hospice care with 421 care centers in 34 states in the US serving ~370,000 patients annually. Over 3,000 hospitals and 59,000 physicians have chosen Amedisys as a partner in post-acute care.

Article continues below advertisement

Analyst recommendations

Of the 11 analysts covering Amedisys in March 2018, three analysts have given the stock a “strong buy” rating. Two analysts have given the stock a “buy” rating, while six analysts have given it a “hold” rating. The mean rating for the stock is 2.3 with a target price of $65.88.

Peer ratings

Of the seven analysts covering BioTelemetry (BEAT) in March 2018, two analysts have given the stock a “strong buy” rating, and five analysts have given it a “buy” rating. The mean rating for the stock is 1.7 with a target price of $44.17.

Of the nine analysts covering Cross Country Healthcare (CCRN) in March 2018, three analysts have given the stock a “buy” or higher rating, while six analysts have given it a “hold” rating with a target price of $12.79.

Of the 20 analysts covering Illumina (ILMN) in March 2018, 14 analysts have given the stock a “buy” or higher rating. Five analysts have given the stock a “hold” rating, while one analyst has given it a “sell” rating. The mean rating for the stock is 1.95 with a target price of $257.6.

In the next part of the series, we’ll take a look at the business segments of Amedisys.

Advertisement

More From Market Realist